MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

87.75
+1.09
+1.26%
After Hours: 87.75 0 0.00% 18:22 04/08 EDT
OPEN
86.74
PREV CLOSE
86.66
HIGH
88.59
LOW
85.95
VOLUME
2.09M
TURNOVER
--
52 WEEK HIGH
96.79
52 WEEK LOW
62.48
MARKET CAP
19.02B
P/E (TTM)
42.75
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INCY stock price target is 92.27 with a high estimate of 124.00 and a low estimate of 74.00.

EPS

INCY News

More
  • Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
  • Zacks · 14h ago
  • Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
  • Zacks · 1d ago
  • Oppenheimer Maintains Outperform on Incyte, Raises Price Target to $90
  • Benzinga · 1d ago
  • Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing
  • MotleyFool.com · 1d ago

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About INCY

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
More

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.